New trial tests precision radiation to fight spread bladder cancer

NCT ID NCT07413523

Recruiting now Disease control Sponsor: Istituto Clinico Humanitas Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is for people with bladder cancer that has spread to a small number of other body parts (up to 3 spots). It compares standard treatment (chemotherapy or immunotherapy) alone versus standard treatment plus a precise, high-dose radiation therapy called SBRT. The goal is to see if adding SBRT helps control the cancer better. About 44 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stereotactic body radiation therapy (SBRT)
What this could lead to: If it works, this could show that adding targeted radiation to standard therapy helps control bladder cancer that has spread to a few places, potentially improving outcomes.
What could go wrong: This is a small early-phase trial with only 44 participants, so results may not apply widely. Radiation can cause side effects, and it is unclear if it will meaningfully improve survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER OLIGOMETASTASIS UROTHELIAL CARCINOMA (UC)

Contacts and locations

Locations

IRCCS Humanitas Research Hospital
RECRUITING

Rozzano, Milan, 20089, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.